Research Summary: Accurate prognostic assessment in patients with cutaneous melanoma is essential as it is one of the most prevalent malignancies in the United States. The American Joint Committee on Cancer (AJCC) staging system remains the cornerstone of risk stratification, but outcomes vary widely among...
Read MoreResearch Summary: Cutaneous melanoma is a significant public health concern, as it is the fifth most common cancer in the United States. Traditional prognostic assessment relies on clinicopathologic features such as Breslow thickness, ulceration status, and mitotic rate, but these factors do not always accurately...
Read MoreThe European Academy of Dermatology and Venereology held its 2025 Annual Meeting from September 17–20, 2025, in Paris, France. The conference gave researchers, physicians, and members of industry the opportunity to share and learn about the latest research in cutaneous oncology, including melanoma. The event...
Read MorePatterns of failure in cutaneous head and neck melanoma following negative sentinel lymph node biopsy: a retrospective cohort study Staibano P, Xie M, Abdallah Z, et al. Am Surg. 2025;91(7):1156–1162. Summary. In this retrospective cohort study, researchers evaluated the risk of recurrence in patients with...
Read MoreResearch Summary: Prieto et al1 compared the performance of two gene expression profile (GEP) tests, clinicopathological (CP)-GEP and 31-GEP, against standard American Joint Committee on Cancer (AJCC) staging in identifying patients with cutaneous melanoma who have a low risk of sentinel lymph node (SLN) positivity,...
Read MoreResearch Summary: Sentinel lymph node biopsy (SLNB) is a standard procedure for staging and management in patients with cutaneous melanoma, aimed at assessing the presence of metastasis in regional lymph nodes. However, SLNB is associated with potential risks and high costs, necessitating accurate patient selection....
Read More©2026 Oncology Matrix. All Rights Reserved.
